DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183496

A cross sectional observational study to find the difference in occurrence of muscle related adverse effects of statins among geriatric and non-geriatric patients

Monica Aggarwal, Shivani Juneja, Muskan Goyal, Tariq Khurana

Abstract


Background: Statins are effectively used for the treatment of dyslipidemias in geriatric patients. The geriatric patients are more vulnerable to experience consequences of drug intensification leading to the manifestation of adverse effects, such as muscle related adverse effects (MRAE) with statins use. The main objective was to find the difference in the occurrence of MRAE of statins among geriatric and non-geriatric users.

Methods: This was a cross-sectional, observational comparative study in which MRAE associated with statins and relevant patient information was noted. Creatine phosphokinase (CPK) levels which are considered as a marker for statin induced muscle damage were obtained for all patients. The different parameters were compared among geriatric and non-geriatric statin users.

Results: Sixty one patients, 28 geriatric (≥60 years) and 33 non-geriatric (<60 years) statin users were enrolled in this study. Ten (38%) geriatric statin users as compared to 6 (20%) non-geriatric statin users were found to have MRAE (P = 0.207). No significant difference in the occurrence of MRAE among geriatric and non-geriatric statin users was found.

Conclusions: The results obtained from the present study suggest that statins are relatively safe, even in older people. There was no evidence to suggest an increased risk of MRAE in geriatric patients receiving statin therapy as compared to non- geriatric patients.


Keywords


Geriatric, Myopathy, Statins

Full Text:

PDF

References


Verri V, Cunha AB, Tessarolo LE, Carneiro RC, Romeo LJ. Reduction of myocardial ischaemia with Simvastatin in addition to conventional treatment in patients with chronic coronary artery disease. Rev port cardiol. 2004;23:1089-105.

McKenney JM, Davidson MH, Jacobson TA, Guyton JR. National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006;97:89C-94C.

Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith SC Jr, et al. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther. 2009;14:49-58.

Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317-24.

Singh H, Chakrawarti A, Guruprasad P, Singh H, Gupta YK. Difference in occurrence of muscle-related adverse effects of statins among male and female geriatric patients: A cross-sectional observational study. Niger Postgrad Med J. 2016;23(4):202-8.

Choudhry NK, Dugani S, Shrank WH, Polinski JM, Stark CE, Gupta R, et al. Despite increased use and sales of statins in India, per capita prescription rates remain far below high‑income countries. Health Aff (Millwood). 2014;33:273‑82.

Abd TT, Jacobson TA. Statin‑induced myopathy: A review and update. Expert Opin Drug Saf. 2011;10:373‑87.

Bays H. Statin safety: An overview and assessment of the data‑2005. Am J Cardiol. 2006;97:6C‑26C.

Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Ame Colle Cardiol. 2002 Aug 7;40(3):567-72.

Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith Jr SC, et al. Management of hyperlipidemia in older adults. J Car Pharmacol Therapeu. 2009 Mar;14(1):49-58.

Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clinical Interventions in Aging. 2013;8:47-59.

Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024-8.

Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 2012;196:50-3.

Gnjidic D, Le Couteur DG, Blyth FM, Travison T, Rogers K, Naganathan V, et al. Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open. 2013;3:e002333.

Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012;10:296-302.

Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85:459-65.

Sathasivam. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317-24.

Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta‐analysis. Br J Clin Pharmacol. 2015;80:363-71.